Group 1 - The company, Mindray Bio-Medical Electronics Co., Ltd., announced an investment of 30 million yuan as a limited partner in the Wuhan Zesen Juxin No. 2 Venture Capital Partnership, with a total fund size of 95 million yuan [2][3] - The company holds a 31.5789% stake in the fund but will not participate in specific investment decisions [2] - The fund primarily invests in equity of unlisted companies within the artificial intelligence infrastructure and terminal industry chain, focusing on sectors like optical interconnection and semiconductors [3] Group 2 - The collaboration with a professional investment institution aims to leverage its resources and management capabilities to enhance the company's investment layout and share in the growth dividends of emerging sectors [3] - The investment is fully funded by the company's own capital [3] - For the first three quarters of 2025, the company reported total operating revenue of 227 million yuan, reflecting a year-on-year growth of 0.53% [3]

Core Viewpoint - Mingde Bio plans to acquire 51% of Hunan Lanyi Medical Instrument Co., Ltd. for 35.71 million yuan, aiming to expand its medical service ecosystem and enhance its capabilities in chronic disease management [1][2]. Group 1: Acquisition Details - The acquisition will occur in two phases, with the first phase involving the purchase of 51% equity for 35.71 million yuan, making Hunan Lanyi a subsidiary of Mingde Bio [1][3]. - The transaction structure includes a capital increase of 20 million yuan for 28.57% equity and a purchase of 15.71 million yuan for 22.43% equity from the existing shareholders [3]. - If Hunan Lanyi meets performance conditions from 2026 to 2028, Mingde Bio will acquire the remaining 49% equity [1][3]. Group 2: Hunan Lanyi Overview - Hunan Lanyi, established in September 2020, focuses on the R&D and production of IVD instruments and reagents, particularly in glycated hemoglobin testing [2]. - The company reported revenues of 30.66 million yuan and a net loss of 23.98 million yuan for the first nine months of 2025, indicating growth potential due to increasing demand in the healthcare sector [2]. Group 3: Strategic Implications - The acquisition aims to create a comprehensive medical service platform that integrates acute and chronic disease management, enhancing service capabilities for healthcare institutions [4]. - Mingde Bio is also pursuing additional acquisitions, including a planned purchase of 100% of Wuhan Bikaier Rescue Supplies Co., Ltd. to further develop its acute care business segment [4].

Core Viewpoint - Mingde Biological has announced a new acquisition plan to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for a total consideration of 35.71 million yuan, with the potential for full ownership if certain performance conditions are met from 2026 to 2028 [1][2] Group 1: Acquisition Details - The acquisition of Hunan Lanyi will be executed in two phases, with the first phase involving an increase in capital and equity acquisition [1] - Hunan Lanyi is currently focused on the research, production, and service of IVD instruments and reagents, particularly in the area of glycosylated hemoglobin testing [1] - The financial performance of Hunan Lanyi shows losses of approximately 20.68 million yuan and 23.98 million yuan for 2024 and the first three quarters of 2025, respectively [2] Group 2: Strategic Rationale - The acquisition is expected to create a natural complement between the core businesses of Mingde Biological and Hunan Lanyi, enhancing the company's comprehensive service capabilities to medical institutions [2] - Mingde Biological aims to expand its product ecosystem and improve its market position in critical care and chronic disease management through this transaction [2][5] Group 3: Financial Performance and Challenges - Mingde Biological reported revenue of approximately 227 million yuan for the first three quarters of 2025, a year-on-year increase of 0.53%, but its net profit decreased by 83.3% to about 13.52 million yuan [4] - The company faces challenges with slow accounts receivable turnover, with a total of approximately 653 million yuan in accounts receivable and a turnover period of 843.4 days [4] - Hunan Lanyi's net assets were negative, amounting to -38.44 million yuan and -62.42 million yuan at the end of 2024 and the third quarter of 2025, respectively [3]

Core Viewpoint - Mingde Bio (002932) has announced its participation in the Wuhan Zesen Juxin No. 2 Venture Capital Partnership, contributing 30 million yuan and holding a 31.5789% stake in the fund, which has a total size of 95 million yuan [1]. Group 1 - The fund, Wuhan Zesen Juxin No. 2, focuses on investment areas such as optoelectronics, semiconductors, artificial intelligence, and high-end manufacturing [1]. - The investment stages covered by the fund include early-stage, growth-stage, and mature-stage investments [1].

Group 1 - The core point of the article is that Mingde Bio (002932) has signed a partnership agreement to invest in a venture capital fund focused on unlisted companies in the AI infrastructure and terminal industry [1] - The total scale of the fund is 950 million yuan, with the company contributing 300 million yuan, representing a 31.5789% stake [1] - The investment areas primarily include equity in unlisted enterprises, particularly in sectors such as optical interconnection and semiconductors [1]

Core Viewpoint - Mingde Bio (002932.SZ) has signed a partnership agreement to invest in the Wuhan Zesen Juxin No. 2 Venture Capital Partnership, with a total fund size of RMB 95 million [1] Investment Details - The fund's total size is RMB 95 million, with Mingde Bio contributing RMB 30 million, representing a 31.5789% stake [1] - Other investors include Wuhan Zesen Changsheng Venture Capital Fund Management Co., Ltd. contributing RMB 100,000 (0.1053% stake), and Hubei Zhenghan Investment Co., Ltd. also contributing RMB 30 million (31.5789% stake) [1] - Additional contributions from individual investors include RMB 10 million from Bao Jie (10.5263% stake), RMB 8 million from Zeng Feng (8.4211% stake), RMB 1 million from Fu Shanshan (10.5263% stake), RMB 200,000 from Cao Ying (2.1053% stake), RMB 4 million from Jiang Lan (4.2105% stake), RMB 800,000 from Zhang Kai (0.8421% stake), and RMB 100,000 from Zhang Ye (0.1053% stake) [1]

Core Viewpoint - Mingde Bio (002932.SZ) has signed a partnership agreement to invest in the Wuhan Zesen Juxin No. 2 Venture Capital Partnership, with a total fund size of RMB 95 million [1] Group 1: Investment Details - The fund has been registered and received a business license from the Wuhan Municipal Market Supervision Administration [1] - Mingde Bio is contributing RMB 30 million, holding a 31.5789% stake in the fund [1] - Other investors include Hubei Zhenghan Investment Co., Ltd. and several individual investors, with contributions ranging from RMB 100,000 to RMB 3 million [1] Group 2: Stake Distribution - The ordinary partner, Wuhan Zesen Changsheng Venture Capital Fund Management Co., Ltd., contributes RMB 100,000, holding a 0.1053% stake [1] - Hubei Zhenghan Investment Co., Ltd. also contributes RMB 30 million for a 31.5789% stake [1] - Individual contributions include RMB 1 million from Bao Jie and Fu Shanshan, each holding a 10.5263% stake, and smaller contributions from other individuals [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）仅作为有限合伙 人参与投资武汉泽森聚芯贰号创业投资合伙企业（有限合伙）（以下简称"泽森 聚芯贰号"或"基金"），不参与泽森聚芯贰号投资项目的相关决策。 2、本次与专业机构共同投资设立私募基金尚处于筹备期，基金尚未完成募 集，基金的设立及投资进展尚存在不确定性；基金投资可能受到宏观经济或行业 环境发生重大变化、政策变化、投资决策失误等多种因素影响，可能存在投资不 能实现预期收益的风险。 公司将密切关注基金设立、运作、投资事项进展情况，严格按照相关规定履 行信息披露义务。敬请广大投资者注意投资风险。 证券代码：002932 证券简称：明德生物 公告编号：2026-004 武汉明德生物科技股份有限公司 关于公司与专业机构共同投资的公告 企业名称：武汉泽森长盛创业投资基金管理有限公司 统一社会信用代码：91420100MABMPURA9J 企业类型：有限责任公司（自然人投资或控股） 一、对外投资概述 1、近日，公司与武汉泽森长盛创业投资基金管理有限公司、湖北 ...

Core Insights - The report highlights a series of policy initiatives aimed at enhancing mergers and acquisitions (M&A) and equity incentive plans, which are expected to invigorate market activity and improve resource allocation in the A-share market [1][6][10] - The report indicates that in December 2025, there were 12 major asset restructuring plans announced, predominantly in the machinery and equipment sector, with a significant number of these plans still in the board proposal stage [10][22] - The report emphasizes the importance of equity incentive plans, noting that 91% of the plans initiated in 2025 have begun implementation, with a focus on the electronics and machinery sectors [27][32] Mergers and Acquisitions Overview - In 2025, a total of 134 major asset restructuring cases were disclosed, with the electronics industry leading the count [6][10] - The December 2025 restructuring cases included significant transactions such as Minmetals Development's acquisition of 100% stakes in Minmetals Mining and Luzhong Mining, aimed at enhancing profitability through the integration of high-margin mineral resources [22][24] - Another notable case involved Mingde Biological's cash acquisition of 100% of Wuhan Bikaier, which aims to create a comprehensive "diagnosis-protection-treatment" ecosystem [23][24] Equity Incentive Plans Overview - In December 2025, 39 new equity incentive plans were announced, with the majority concentrated in the electronics and machinery sectors, and most plans representing 1% to 2% of the total share capital [32][39] - The report notes that the majority of equity incentive plans have been implemented, with a small percentage still pending approval from shareholders [27][30] - The report provides a list of noteworthy companies involved in equity incentive plans, including ShenNan Circuit and Baosteel, highlighting their respective market capitalizations and the proportion of shares involved in the incentive plans [39]

Group 1: Core Insights - The report highlights that the A-share market is expected to gain momentum through accelerated mergers and acquisitions (M&A) and stock incentive plans, driven by supportive policies from the China Securities Regulatory Commission (CSRC) [8][12][18] - In December 2025, a total of 12 major asset restructuring plans were announced, predominantly in the machinery and equipment sector, with over half currently in the board proposal stage [12][22] - The report identifies key cases of interest, including WISCO's acquisition of 100% equity in WISCO Mining and Luzhong Mining, which aims to transition the company’s main business to black metal mining [22][24] Group 2: M&A Overview - In 2025, there were 134 disclosed major asset restructuring cases, with the electronics industry leading the count [8][12] - The report notes that the majority of December's restructuring cases involved companies with a market capitalization of less than 5 billion, indicating a trend towards smaller firms engaging in M&A [12][18] - The primary motives for these restructurings were strategic cooperation and horizontal integration, with 5 and 4 cases respectively [12][22] Group 3: Stock Incentive Plans - Approximately 91% of the stock incentive plans announced in 2025 have begun implementation, indicating strong engagement from companies in this area [28][33] - In December 2025, 39 new stock incentive plans were released, with the electronics and machinery sectors being the most active [33][41] - The majority of these plans had an incentive total that represented 1% to 2% of the total share capital, reflecting a conservative approach to equity incentives [33][41]